R&D tax relief is becoming harder to treat as cash in the bank
R&D tax relief can still support investment, but an SME should not treat an expected claim as available cash until eligibility, evidence, timing and payment are understood. New commercial research found that 62% of surveyed R&D-active SME finance chiefs had reduced investment following the reforms, while 30% said delays or uncertainty had led them to take out loans.
The sensible approach is to fund the project on a downside case. Treat the relief as a potential source of cash, not a guaranteed payment date.
Quick summary
- RCK Partners commissioned Censuswide to survey 254 CFOs at R&D-active UK SMEs between 1 and 7 July 2026.
- The survey reported that 62% had reduced R&D investment, 35% hired fewer technical staff, 29% delayed projects and 20% cancelled projects.
- Thirty per cent said delays or uncertainty had led them to borrow, and 72% said processing and payment timing was too unreliable to use confidently in planning.
- This is a commissioned survey of a targeted group, not an official measure of all UK SMEs.
- HMRC now operates the merged R&D expenditure credit scheme and enhanced R&D intensive support for accounting periods beginning on or after 1 April 2024, with detailed eligibility and information requirements.
The business problem
R&D consumes cash before it creates a commercial return.
Engineers, developers, materials, testing and subcontractors are paid now. The new product, process or software may not generate revenue for months or years. Tax relief can help rebalance that cost, but only after the business has incurred qualifying expenditure and completed the claim process.
The cash problem appears when a forecast treats the relief as certain, fixed-date money. If the claim is delayed, reduced, challenged or found ineligible, wages and project costs still have to be paid.
What the new survey tells us — and what it does not
The RCK Partners research is useful because it focuses directly on finance leaders in R&D-active SMEs. It suggests that uncertainty is changing real decisions on hiring, projects and funding.
It also has limits. RCK is an R&D tax advisory business, the research was commissioned, and the sample was 254 CFOs who had claimed or considered claiming relief in the previous five years. The results should not be presented as proof that 62% of all UK SMEs have cut R&D.
The fair conclusion is narrower: among the targeted businesses surveyed, reform and claim uncertainty were widely reported as a material investment and cash-flow issue.
Why the checks have become tougher
R&D tax relief has faced serious error, fraud and poor-adviser problems. Tougher evidence, notification and compliance requirements are intended to protect public money and direct support towards genuine innovation.
Most SMEs are honest. But a small number of bad actors and poor advisers have promoted weak or ineligible claims. That makes HMRC and funders more cautious and increases the evidence burden for everyone else.
The answer is not to weaken records. It is to make the technical case, cost evidence and governance strong enough to survive proper review.
How funding can help
General working-capital facility
A revolving facility or term loan may support the wider business while the claim is processed. The lender will normally assess repayment from the whole business, not simply accept the claim value.
Invoice finance
Where the business also has commercial receivables, funding against valid invoices may be more reliable than borrowing against a future tax outcome.
Equity or director funding
R&D with a long or uncertain route to revenue may be better suited to patient capital than short-term debt. Director money can be flexible but creates personal exposure and should be documented properly.
Specialist claim-linked funding
Some providers will consider funding linked to an expected R&D benefit. This can accelerate cash, but the business must understand what happens if HMRC delays, reduces or rejects the claim. The loan normally remains payable.
When bridging can work
- The project and expenditure have been independently and conservatively assessed.
- The business has a strong claim history and good technical records.
- The forecast does not depend on an exact payment date.
- The facility can be repaid from trading or other cash if the claim is delayed.
- The funding term allows for a realistic compliance timetable.
- The business has enough runway to answer HMRC questions properly rather than rushing the process.
- The adviser is credible, transparent on fees and willing to stand behind the technical work.
Where it can go wrong
- The claim is treated as certain before the eligibility work is complete.
- A lender advances against an aggressive estimate rather than a conservative value.
- The business has no repayment source if the claim is delayed or reduced.
- The adviser is paid only on success and pushes the claim value without explaining risk.
- Technical records were created after the event and do not match the project reality.
- The company cannot explain which costs qualify and why.
- Borrowing keeps a project alive even though the commercial case has weakened.
- A director signs a personal guarantee believing HMRC will automatically repay the debt.
Tax relief can improve a viable R&D plan. It should not be used to make an unviable project appear funded.
Costs, risks and watch-outs
Claim-linked funding may include interest, arrangement fees, legal costs, monitoring requirements and a lender discount to the expected claim. The lender may also require wider business security or a personal guarantee.
The central risk is mismatch. The loan has a fixed legal repayment obligation. The relief depends on eligibility, evidence, calculation, submission and HMRC processing.
Build a forecast where the claim is delayed by at least several months and another where it is materially reduced. If either scenario makes the business insolvent, the funding structure is too fragile.
Questions to ask before signing
- Is the facility repayable even if HMRC rejects or reduces the claim?
- Who has validated the technical eligibility and qualifying cost schedule?
- What value has the lender placed on the claim and what discount has been applied?
- What is the total cost if payment is delayed by three, six or twelve months?
- What security and personal guarantee are required?
- Can the lender demand repayment after an HMRC enquiry starts?
- What information must be supplied during the facility?
- Can the business repay from normal trading if the claim is not paid?
- Are there exit, extension or default fees?
- Is patient equity more suitable than short-term debt?
- Is the R&D project commercially viable without the relief?
What lenders will check and why
A lender needs evidence that the expected benefit is credible and that the business can repay even if the timetable changes.
- The technical project description and qualifying uncertainty.
- Contemporaneous project records and staff time evidence.
- The qualifying expenditure schedule.
- Company Tax Return and additional information submissions.
- Previous R&D claims, payments and enquiries.
- The adviser’s credentials and engagement terms.
- Bank statements, management accounts and runway.
- HMRC liabilities and wider tax compliance.
- Existing debt, security and director support.
- A downside cash-flow forecast.
Good evidence protects the market. It helps genuine innovators distinguish themselves from weak claims and gives funders a clearer basis for risk.
Final practical summary
R&D tax relief remains a potentially valuable part of the UK innovation funding landscape. But the rules, evidence and timing need to be taken seriously.
An SME should not spend the expected claim twice: once on the project and again in a forecast that assumes prompt payment.
Use conservative numbers. Keep records as the work happens. Fund the downside case. Where debt is used, make sure the business can repay it without depending entirely on HMRC paying the amount and date originally expected.
FAQ
Can a business borrow against an R&D claim?
Potentially, depending on the provider, claim quality and wider business. The borrowing remains a debt and may still be repayable if the claim is challenged or reduced.
Which R&D scheme now applies?
For accounting periods beginning on or after 1 April 2024, HMRC says the merged R&D expenditure credit scheme or enhanced R&D intensive support may apply, depending on the company and circumstances.
What is the biggest cash-flow mistake?
Treating an estimated claim as guaranteed cash on a fixed date. A robust plan allows for delay, reduction and questions.
Sources and further reading
- RCK Partners — R&D tax credit reforms are stifling UK innovation. Commissioned Censuswide survey; source for methodology and reported percentages.
- The Times — Crackdown on tax fraud makes businesses slash research. Independent reporting and Government response; may require a subscription.
- GOV.UK — Claiming Research and Development tax relief. Official HMRC claim steps, eligibility links and warning that ineligible claims may attract penalties.
- GOV.UK — Merged R&D expenditure credit and enhanced R&D intensive support. Official current scheme guidance for accounting periods beginning on or after 1 April 2024.
This article reflects current Juno Funding editorial. Funding products, rates and lender appetite change frequently — figures are indicative only and should not be treated as advice.